FIELD: medicine, endocrinology, pharmacology, pharmacy.
SUBSTANCE: invention relates to a pharmaceutical combined composition used for treatment or prophylaxis of hypertension in patients suffering with diabetes mellitus. The composition comprises AT1-antagonist valsartan or its pharmaceutically acceptable salt and calcium channel blocking agent or its pharmaceutically acceptable salt, and pharmaceutically acceptable carrier. The composition elicits synergistic effect and expanded spectrum effect.
EFFECT: improved and valuable medicinal properties of composition.
10 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CANAL BLOCKERS | 1999 |
|
RU2450813C2 |
| COMBINATION OF ORGANIC COMPOUNDS | 2003 |
|
RU2324482C2 |
| SYNERGETIC COMBINATIONS CONTAINING RENIN INHIBITOR AND INTENDED FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2006 |
|
RU2346703C2 |
| RENIN INHIBITOR-CONTAINING SYNERGETIC COMPOSITIONS DESIGNATED FOR TREATMENT OF CARDIOVASCULAR DISEASE | 2001 |
|
RU2310443C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| COMBINATION OF DIPEPTIDILPEPTIDASE IV (DPP IV) INHIBITOR AND CARDIOVASCULAR SUBSTANCE | 2003 |
|
RU2336876C2 |
| PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) | 2003 |
|
RU2334513C2 |
| SALT OF ALISKIREN AND SULFURIC ACID | 2007 |
|
RU2439054C2 |
| APPLICATION OF ORGANIC COMPOUNDS | 2005 |
|
RU2426532C2 |
| METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
